About Northstar Study

The Northstar Study (HGB-204), a Phase 1/2 study, is fully enrolled and is in the follow-up phase of the study. Early data from the Northstar Study shows that patients with non-β00 genotypes and ≥12 months of follow up have stopped regular transfusions; patients with β00 genotypes and ≥12 months of follow up had a median reduction in transfusion volume of 63%.